PubMed Health⌕ Search

Biomedical subjects

P Mandulova

Publications and source records attributed to P Mandulova.

10 recordsLinked to original sources
PubMed1999

Functional parameters in pulmonary bullous emphysema.

OBJECTIVE: 1. compare a large set of functional parameters in patients with bullous emphysema and patients with nonbullous emphysema. 2. To compare a chest radiographs (CHR) and a high resolution computed tomography (HRCT) in the clinical assessment of bullous emphysema. MATERIAL AND METHODS: The study population included 43 stable COPD patients (age = 59 +/- 9 years; pack/year (P/Y) = 39 +/- 19; ATS dyspnea score = 2.3 +/- 0.9; FEV1%pred. = 30 +/- = 10%; KCO%pred. = 49 +/- 16%; 6MWD (six minute walk distance) = 395 +/- 103 m; mean +/- SD). The patients were divided into two groups (patients with and without bullae) by a HRCT. In most of the cases the size of the bullae, measured by CT scan, was less than 15 mm. Twenty two CHRs were read independently by three experienced chest radiologists who had no knowledge of the CT scan data. RESULTS: Statistically significant differences were found between the groups with bullous (n = 19) and nonbullous (n = 24) emphysema in FEV1 (p < 0.001); VC (p = 0.001); BMI (p = 0.018); Borg after exercise (p = 0.021); FEV1/VC% (p = 0.025) and P/Y (p = 0.034). The sensitivity of chest radiographs compared with CT scan regarding the small bullae was very low: 27.7% in radiologist I, 12.3% in radiologist II, and 21.5% in radiologist III. CONCLUSIONS: 1. The patients with bullous emphysema have statistically significant lower lung function indices (FEV1, VC, FEV1/VC%) and BMI than those with nonbullous emphysema. 2. Patients with bullous emphysema have higher level of dyspnea score after 6MWD and higher pack-year smoking status than those with nonbullous emphysema. 3. For the clinical evaluation of emphysema the information derived from a standardised reading of the CXR is not as valuable as that derived from the CT scan.

Aged↗
PubMed1982

BCG immunotherapy of lung cancer in a district oncology dispensary. I. Study of 860 patients with histologic diagnosis.

The investigation refers to lung cancer patients registered in an oncology dispensary from 1965 to 1975. The conventional treatment (surgery, radiotherapy and chemotherapy) has covered 35.9% of all patients, whereas immunotherapy with BCG or with its soluble fraction has been applied in 46.2% of them. Immunotherapy has mainly been applied to epidermoid carcinoma and large-cell carcinoma. Comparing the survival of immunotherapy treated with non-immunotherapy treated patients it was found that in Stage I-II group the difference in favor of immunotherapy was significant in the second year of observation and in Stage III group a significant difference was found in all observation periods (1-5 years). In Stage I-II the 5-year survival rate of immunotherapy treated patients (13.2%) was similar to the survival rate of operated patients (13.7%). Immunotherapy in large cell carcinoma showed significantly better results than immunotherapy in epidermoid carcinoma. Immunotherapy with BCG and F70 was applied as an independent treatment of lung cancer. When applied to patients primarily operated, radiation or chemotherapy treated, the survival was significantly higher than the survival of patients submitted to conventional treatment or to immunotherapy separately.

Adenocarcinoma↗
PubMed1980

Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F70) after surgery, radiotherapy and chemotherapy.

243 lung cancer patients treated with routine therapy (surgery 54, radiotherapy 46 and chemotherapy 143) in Plovdiv's District Oncologic Dispensary (PDOD) were submitted to an additional therapy with BCG or with its soluble fraction F70. The survival rate of these patients was compared with the survival rate of 305 lung cancer patients following routine therapy alone (surgery 78, radiotherapy 113 and chemotherapy 114). The two groups were not randomized. Between patients treated and non-treated with BCG(F70) a significant increase of the survival rate was found for patients submitted to BCG(F70) treatment after surgery or radiotherapy in the 2nd and 3rd year survival period and for patients submitted to BCG(F70) treatment after chemotherapy -- in the 1st year survival period of patients with limited disease only. The effect of the additional BCG(F70) treatment was less dependent on the preceding routine therapy than upon the clinical stage of the disease at the moment of BCG(F70) treatment beginning. More salient results were observed in patients with undifferentiated histological forms.

BCG Vaccine↗
PubMed1979

Investigations on the methods of clinical application of a soluble BCG fraction (F70) in lung cancer.

Several parameters for an optimal treatment scheme of a soluble BCG fraction (F70) were investigated. Among lung cancer patients treated with F70 a restricted selection was made of patients treated with small doses (5--10 U) every second or third month (sparing scheme) and of patients treated every month with sharply increasing doses up to tens of thousands units (aggressive scheme). It was found that the survival rate and the rate of marked X-ray regressions were higher in the former group. As it was previously established for lung cancer patients treated with living BCG, in the group of sparing scheme-treated patients the longest survival period pertained to patients treated once and patients treated twice or three times and an inverse correlation existed between the number of applications of F70 and the mean survival period. It was concluded that, as with living BCG, a sparing approach to the immunotherapy of lung cancer with F70 is to be preferred to an aggressive approach. Illustrative cases treated once, twice and three times are presented.

Aged↗
PubMed1976

Survival rate in lung cancer.

The authors followed the survival rate in 927 patients with lung cancer treated in the oncological dispensary of the Plovdiv City during 1965--1972. 41.3% of the patients were in stage 1--11, 19.9%--in stage III, 38.8%--in stage iv. Of all the patients 8.2% were operated upon, in 14.7%--radiotherapy was employed, 9.9% of the patients were treated pharmacologically, 67.5% of cases were not treated at all. As a result of all kinds of treatment 21.4% of the patients survived for one year, and 1.1%--for 5 years. It is concluded that the search for new methods of the treatment and early diagnosis of lung cancer is quite essential.

Bulgaria↗